4/1/2019 7:43:21 AM
Endologix Reiterates 2019 Guidance; Announces Equity Financing Of $52 Mln
1/10/2019 8:03:14 AM
Endologix Appoints John Zehren As Chief Commercial Officer
1/7/2019 8:10:47 AM
Endologix Expects Revenue Of $34 Mln For Q4, $155.8 Mln For 2018
10/25/2018 10:22:31 AM
Endologix Announces Pricing Of Underwritten Public Offering Of Common Stock For Net Proceeds Of $20.0 Mln
10/2/2018 4:02:32 PM
Endologix Expects Q3 Revenues In Range Of $34.3 Mln-$34.7 Mln
8/15/2018 8:03:42 AM
Endologix Appoints Jeffrey Brown As Chief Operations Officer
6/28/2018 8:04:15 AM
Endologix Announces Positive 1-Year Results From Ovation LUCY Study
6/25/2018 4:03:08 PM
Endologix Appoints Jeffry Fecho As Chief Quality Officer
2/5/2018 8:08:57 AM
Endologix Completes Patient Enrollment In ELEVATE IDE Clinical Study
2/23/2017 8:44:37 AM
RBC Capital Markets Is Cutting Endologix Inc. (ELGX) 4Q17 Rev. Estimate To 54.9 M From 56.3 M
2/23/2017 8:44:22 AM
RBC Capital Markets Is Cutting Endologix Inc. (ELGX) 3Q17 Rev. Estimate To 50.6 M From 51.4 M
2/23/2017 8:43:55 AM
RBC Capital Markets Is Increasing Endologix Inc. (ELGX) 2Q17 Rev. Estimate To 50.0 M From 48.4 M
2/23/2017 8:43:38 AM
RBC Capital Markets Is Cutting Endologix Inc. (ELGX) 1Q17 Rev. Estimate To 41.4 M From 46.1 M
2/23/2017 8:43:17 AM
RBC Capital Markets Is Lowering Endologix Inc. (ELGX) 2018 Rev. Estimate To 216.8 M From 222.5 M
2/23/2017 8:42:47 AM
RBC Capital Markets Is Cutting Endologix Inc. (ELGX) 2017 Rev. Estimate To 197.0 M From 202.2 M
11/2/2016 6:42:50 AM
RBC Capital Markets Is Lowering Endologix Inc. (ELGX) Q4 16 Rev. Estimate To 52.5 M From 56.5 M